June 13, 2022 8:12am
After two (2) rough and shaken falls, challenge and climb it; let RMi do the footwork for you
As I am VERY concerned by sector LOWS and ability to comeback and, there is value out there
Pre-open indications: 7 Negative Indications, 1 Positive Indication, 1 Puff/Pump/Promote
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
The 8:00 A.M., ET edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -1.90% (-596 points), S&P futures are DOWN -2.38% (-92 points) and NASDAQ futures are DOWN -3% (-356 points) early in the pre-open – so far,
U.S. stock futures dropped on Monday morning,
European stocks tumbled,
Asia-Pacific stocks declined.
Henry’omics:
Friday’s CPI report dashed cell and gene therapy sector hopes …as three (3) negative and two (2) positive closes ended the week.
Indexes dropped, the Dow fell -880 points or -2.735, the S&P 116.96 or -2.91% as the Nasdaq dived -414.20 or -3.52% on Friday after a highly anticipated inflation report showed a faster-than-expected rise in prices and consumer sentiment hit a record low.
For the week, the Dow lost -4.585, her S&P -5% and the Nasdaq -5.60% - its worst since January.
Economic Data Docket: The Fed will dominate the conversation for investors this week with a policy meeting to be held on Tuesday and Wednesday, June 14-15 expecting at least another 0.50% increase in its benchmark interest rate on Wednesday afternoon at 2 p.m. The Fed will also release its latest summary of economic projections on Wednesday, offering officials' forecasts for GDP growth, inflation, and future rate hikes.
RegMed Investors’ (RMi) closing bell: “share price shredding and destruction continues” … https://www.regmedinvestors.com/articles/12469
Ebb and flow –
Q2/22 –
June – 4 positive and 4 negative closes
· May - 11 positive and 10 negative closes
· April - 1 holiday, 6 positive and 13 negative closes
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Positive Upside Indications:
Ionis Pharmaceuticals (IONS) closed down -$0.17 to $34.76 <52-week low of $25.04> with a positive +$0.91 or +2.62% pre-open indication,
Negative Downside Indication:
uniQure NV (QURE) closed down -$1.23 to $14.24 <52-week low of $12.52> with a negative -$0.16 or -1.12% pre-open indication,
Verve Therapeutics (VERV) closed down -$1.43 to $12.61 <52-week low of $11.30> with a negative -$0.11 or +0.87% pre-open indication,
Beam Therapeutics (BEAM) closed down -$3.71 to $33.08 <52-week low of $27.77> with a negative -$1.09 or +3.33% pre-open indication.
Intellia Therapeutics (NTLA) closed down -$7.69 to $42.45 <52-week low of $38.85> with a negative -$1.88 or -4.43% pre-open indication,
uniQure NV (QURE) closed down -$1.23 to $14.24 <52-week low of $12.52> with a negative -$0.16 or -1.12% pre-open indication,
CRISPR Therapeutics (CRSP) closed down -$7.94 to $63.76 <52-week low of $42.51> with a negative -$2.86 or -4.499% pre-open indication,
Fate Therapeutics (FATE) closed down -$3.67 to $19.81 <52-weel low of $19.62> with a negative -$0.74 or -3.74% pre-open indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed up +$0.065 with 295 shares traded on Friday following Thursday’s $0.00 with 43 shares traded, Wednesday with 2 shares traded, Tuesday’s $0.00 at $4.68 with 65 shares traded, and last Monday’s +$0.23 with 3,575 shares.
WARNING: Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing. is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?
· So, Has BSTG filed its Annual Report to the FDA, isn’t it a “Material Fact”?
· Is yet ANOTHER financing on-going of 5+M shares being prepared to be sold?
The BOTTOM LINE:There is VALUE out there however, it’s about playing or betting the timing of the sector.
The cell and gene therapy suffered significant losses Thursday and Friday, with the major indexes undercutting key short-term support. Surrounding the sector’s coverage group, decliners trounced winners.
Investors should be reducing exposure. The market action, especially in cell and gene therapy stocks, has been weak.
We are left with choosing to hang on to them; but, given the sector shifts and the fierce, sudden sell-offs, investors may want to at least consider taking partial profits – when they can.
The stock market rally had its worst day in weeks. The major indexes closed below their 21-day moving averages for the first time since late May and undercut their June intraday lows. <IBD>
I STILL haven’t heard the bugle sound of a sustainable advance or rally … rising rates and slowing economic growth are not a supportive environment for investors.
Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resistance or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …
This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
